{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:47:52Z","timestamp":1790635672645,"version":"4.1.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1097\/mpa.0b013e3182328045","type":"journal-article","created":{"date-parts":[[2011,11,30]],"date-time":"2011-11-30T07:14:27Z","timestamp":1322637267000},"page":"461-466","source":"Crossref","is-referenced-by-count":149,"title":["Comparison of Health-Related Quality of Life in Patients With Neuroendocrine Tumors With Quality of Life in the General US Population"],"prefix":"10.1097","volume":"41","author":[{"given":"Jennifer L.","family":"Beaumont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria T.","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210212","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","volume":"25","author":"Kaltsas","year":"2004","journal-title":"Endocr Rev"},{"key":"R2-16-20210212","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u2019\u2019carcinoid\u2019\u2019: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R3-16-20210212","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11102-006-0271-4","article-title":"Treatment of neuroendocrine tumors with somatostatin analogs","volume":"9","author":"Janson","year":"2006","journal-title":"Pituitary"},{"key":"R4-16-20210212","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008215730767","article-title":"Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center","volume":"8","author":"Janson","year":"1997","journal-title":"Ann Oncol"},{"key":"R5-16-20210212","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-5-18","article-title":"Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study","volume":"5","author":"Frojd","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"R6-16-20210212","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11136-009-9487-x","article-title":"Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population","volume":"18","author":"Haugland","year":"2009","journal-title":"Qual Life Res"},{"key":"R7-16-20210212","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.3748\/wjg.15.5067","article-title":"Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas","volume":"15","author":"Pezzilli","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R8-16-20210212","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1471-6712.2008.00596.x","article-title":"Is satisfaction with doctors\u2019 care related to health-related quality of life, anxiety and depression among patients with carcinoid tumours? A longitudinal report","volume":"23","author":"Frojd","year":"2009","journal-title":"Scand J Caring Sci"},{"key":"R9-16-20210212","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1365-2354.2003.00322.x","article-title":"Distress, quality of life and strategies to \u2018keep a good mood\u2019 in patients with carcinoid tumours: patient and staff perceptions","volume":"12","author":"Larsson","year":"2003","journal-title":"Eur J Cancer Care (Engl"},{"key":"R10-16-20210212","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2354.2007.00844.x","article-title":"Anemia in patients with midgut carcinoid, treated with alpha interferon: effects by erythropoietin treatment on the perceived quality of life","volume":"17","author":"Larsson","year":"2008","journal-title":"Eur J Cancer Care (Engl"},{"key":"R11-16-20210212","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2354.2007.00781.x","article-title":"Are importance-satisfaction discrepancies with regard to ratings of specific health-related quality-of-life aspects valid indicators of disease- and treatment-related distress among patients with endocrine gastrointestinal tumours?","volume":"16","author":"Larsson","year":"2007","journal-title":"Eur J Cancer Care (Engl"},{"key":"R12-16-20210212","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/02841860152703445","article-title":"Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours","volume":"40","author":"Larsson","year":"2001","journal-title":"Acta Oncol"},{"key":"R13-16-20210212","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1008360718646","article-title":"Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours","volume":"10","author":"Larsson","year":"1999","journal-title":"Ann Oncol"},{"key":"R14-16-20210212","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00002820-199812000-00005","article-title":"Quality of life in patients with endocrine tumors of the gastrointestinal tract: patient and staff perceptions","volume":"21","author":"Larsson","year":"1998","journal-title":"Cancer Nurs"},{"key":"R15-16-20210212","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/028418699432022","article-title":"Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract","volume":"38","author":"Larsson","year":"1999","journal-title":"Acta Oncol"},{"key":"R16-16-20210212","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1365-2354.2002.00293.x","article-title":"\u2018Satisfaction with care\u2019: associations with health-related quality of life and psychosocial function among Swedish patients with endocrine gastrointestinal tumours","volume":"11","author":"Von Essen","year":"2002","journal-title":"Eur J Cancer Care (Engl"},{"key":"R17-16-20210212","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.2004.10.016","article-title":"Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"22","author":"Teunissen","year":"2004","journal-title":"J Clin Oncol"},{"key":"R20-16-20210212","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jclinepi.2004.01.012","article-title":"A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale","volume":"57","author":"Eton","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"R22-16-20210212","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejca.2005.10.025","article-title":"Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours","volume":"42","author":"Davies","year":"2006","journal-title":"Eur J Cancer"},{"key":"R23-16-20210212","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/MPA.0b013e31819b6441","article-title":"Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors","volume":"38","author":"Vinik","year":"2009","journal-title":"Pancreas"},{"key":"R24-16-20210212","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R25-16-20210212","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1200\/JCO.1999.17.4.1111","article-title":"Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms","volume":"17","author":"Wymenga","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPA.0b013e3182328045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:25:06Z","timestamp":1786047906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006676-201204000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0b013e3182328045","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}